drug development

Katalin Karikó and Drew Weissman received this year’s Physiology or Medicine award for their work on RNA biology and mRNA-based vaccines.

Matthew Disney’s idea of small molecules that target RNA once seemed fanciful. Now, even the pharma industry is pursuing it

Drug repurposing uses existing drugs beyond the scope in which they were originally approved by the Food and Drug Administration.

A new machine learning model promises fast prediction of drug-target interactions.

Researchers created a new high-throughput tool to hunt for therapies that remyelinate the nervous system.

A battery that charges itself in salty fluids starves tumors of oxygen, helping improve some drugs treat cancer, a study finds.

Scientists developed a standardized multiplex immunohistochemistry and RNA in situ hybridization protocol using ChipCytometry^TM.

A hormone naturally induced by alcohol consumption accelerates the recovery of mice after binge drinking by activating neurons involved in arousal and alertness.

The antidepressant properties of hallucinogenic drugs may stem from their ability to bind to intracellular serotonin receptors, a study suggests.

Synthetic variations of squalene, which is used to boost immune responses, could make vaccines more effective while reducing fisheries for struggling sharks.

Multiple candidates are in Phase 3 clinical trials for older adults and pregnant women, with some getting close to approval in the United States.

The “on demand” drug immobilizes sperm rather than limit their production, preventing 100 percent of pregnancies in an experiment.

Researchers learned how IGFBP7, a senescence signaling protein and biomarker, promotes cardiac remodeling and cellular aging.

In both the laboratory and clinic, scientists harness viral genetic transfer capabilities to develop gene therapies that modulate cellular function.